Blue Water Acquisition Corp

Blue Water Acquisition — SPAC Merger (June 2021)

34 slides from Blue Water Acquisition's SPAC merger presentation, Jun 9, 2021

  1. Slide 1: Corporate Presentation June 2021

    CORPORATE PRESENTATION J U N E 202 1 INNOVATING FOR BETTER HEALTH

  2. Slide 2: Disclaimer

    DISCLAIMER This presentation (“Presentation”) is for informational purposes only and is being furnished solely for the purpose of assisting interested parties in making their own evaluation with respect to a potential transaction involving Blue Water Acquisition Corp. (“Blue Water”) and Clarus Thera

  3. Slide 3: Disclaimer (Cont'd)

    DISCLAIMER (CONT’D) This Presentation does not purport to summarize all of the conditions, risks and other attributes of an investment in Blue Water or Clarus. Information contained herein will be superseded by, and is qualified in its entirety by reference to, any other information that is made ava

  4. Slide 4: Clarus Leadership Team and Board

    R O BERT DUDLEY, PH . D P r esident & C EO • Over 30 years experience in TRT field • Clarus co - founder • Extensive R&D experience and partnership with the FDA • Co - inventor and developer of AndroGel 1% • Co - inventor of JATENZO • Track record of success with public company • Abbott, Solvay, Uni

  5. Slide 5: Clarus Leadership Team (Cont'd)

    FRANK JAEG E R , MA , MBA Chie f C o mmerci a l Of ficer • Significant Medical Affairs experience • Multiple therapeutic area experience including TRT & Men's Health • Medical science liaison (MSL) team management • AbbVie, Abbott, Solvay, Searle Medical Affairs Support L a Tonya Wri g ht VP, Sales

  6. Slide 6: Blue Water Leadership Team and Board

    • 25+ years of experience in healthcare • Founded or led 8 healthcare and pharmaceutical companies (i.e. Innovative Biosensors, Blue Water Vaccines, Noachis Terra) • Previously Chairman of Microlin Bio, Ember Therapeutics, Sydys Corporation JOE H ERNA N DEZ , MS , MBA Chairman and CEO BLU E WATER LE

  7. Slide 7: Investment Thesis

    1 2 5 3 4 JATENZO is an FDA approved, first - in - class and only oral testosterone replacement therapy (“TRT”) of its kind to capture market share & expand the large U.S. market Significant and growing market opportunity (~ 8 MM annual scripts in the U . S . ) with each JATENZO market share point a

  8. Slide 8: The JATENZO Opportunity

    8 THE JATENZO O PP O R T U N I T Y

  9. Slide 9: Hypogonadism Overview

    HYPOGONADIS M OVERVIEW T E ST O ST E R O N E D E F I C I E N C Y I N M E N ( H Y PO G O N A D I SM ) I S A L A R G E A N D A T T R A C T I V E M A R K E T O PPO R T U N I T Y Male Hypogonadism Prevalence ~20MM Diag n os e d Patients ~6MM C u rrently Treated Patients ~2.2MM Existing Patients ~1.5MM N

  10. Slide 10: Timeline of Select TRT FDA Approvals

    2014 2010 2003 Earlier 1995 1996 1997 1998 1999 2000 2001 2002 2015 2016 2017 2018 2019 TIM E L I N E O F S E L E C T TR T FDA APP R OVA L S Injection / Pellets Patch T opi c al Buc cal Na s al Gel O r al Methyltestosterone (1950’s; Liver Toxicity) Injectable T - esters (1950’s) PRE - JATENZO TREATM

  11. Slide 11: Importance of an Oral TRT Option

    The C ycl e o f Disconti n ua t ion More than 95,000 men change TRTs at least once per year* Curren t Non - ora l Trea t m e nts Po s e Administration Challenges • Injectio n pain • Procedures • Mess, drying time • Transferen c e to partner/kids • Skin irritation • Gum irr i tation/diso r d e rs • N

  12. Slide 12: The JATENZO Opportunity

    THE J ATEN Z O OPPORTUNITY F I R ST O R A L T O F I T S K I N D A PPR O V E D B Y F D A – A L O N G - A W A I T E D A D V A N C E! CONVENIENT • Easy - to - swallow soft gel taken BID with food (twice daily) • Dose adjustable, if necessary EFFECTIVE • 87% o f me n achi e ved T levels in norma l range

  13. Slide 13: JATENZO Product Differentiators

    JATE N ZO P R ODUC T DI F FE R ENTIATORS A SA F E O R A L W I T H O U T L I V E R T O X I C I T Y A D D R E SSE S C O M M O N C O N C E R N S SE E N W I T H I N J E C T I O N S A N D G E L S LACK O F A SAFE AN D EFF E CTIV E ORA L T ES T OSTER O NE INJECTABLE T PRODUCTS CAN BE PAINFUL AND CARRY SIGN

  14. Slide 14: Symptom Improvement

    SYMPTOM IMPROVEMENT JA T E N Z O I N C R E A SE S F R E E T E ST O ST E R O N E A N D I M PR O V E S C L A SSI C SI G N S A N D S Y M PT O M S A S S O C I A T E D W I T H H Y PO G O N A D I S M Increased Bone Mineral Density Improved Body Composition Improved Psychosexual Symptoms Increased Free (Ac

  15. Slide 15: JATENZO Safety Profile

    Adverse Reactions ≥ 2% in 4 - Month Pivotal Trial of JATENZO JATENZO WAS SHOWN TO BE SAFE AND WELL - TOLERATED J A T E N Z O S A F E T Y P R O F I L E C O N S I S T E N T W I T H T R T C L A S S R e f e r e n c es : Swerdloff, RS and Dudley, RE. Ther Adv Ur o l 2020; 12: 1 - 16; Swerdloff, RS, et al

  16. Slide 16: Healthcare Providers and Patients Like JATENZO

    “All of our TRT patients ask about different options. This is amazing. Finally.” “This is an innovative game changer, and this product will do very well.” “An oral has been the Holy Grail of Testosterone.” “This is going to put all the other TRTs out of business.” “Patients are going to love this.”

  17. Slide 17: TRT Market Performance in 2020

    70 0 , 0 00 60 0 , 0 00 50 0 , 0 00 40 0 , 0 00 30 0 , 0 00 20 0 , 0 00 80 0 , 0 00 Jan - 19 Fe b - 1 9 Mar - 19 Apr - 19 May - 19 Jun - 19 Jul - 19 Aug - 19 Sep - 19 Oct - 19 Nov - 19 Dec - 19 Jan - 20 Feb - 20 Mar - 20 Apr - 20 May - 20 Jun - 20 Jul - 20 Aug - 20 Sep - 20 Oct - 20 Nov - 20 Dec - 2

  18. Slide 18: Focused Targeting

    FOCUSED T ARG E TING C L A R U S I S E N G A G I N G T H E K E Y T R T H C P’ S A N D T H E PA T I E N T S T H E Y T R E A T Endocrinologi s ts , Urologis ts , Primar y Car e P h ysicians Targeting Deciles 8 - 10 Healthcare Providers 55 Territories = 62% TRT Market Coverage 10 0 T e r r i t o r i e

  19. Slide 19: Patient Support and Savings

    PATI E NT SUPPORT AND SAVINGS M O S T C O M M E R C I A L C O V E R E D PA T I E N T S W I L L PA Y $ 0 F O R T H E I R PR E S C R I PT I O N TRT Marke t (Dec . 2020) Data Source: Symphony Health PrescriberSource data, December 2020 18 19

  20. Slide 20: Commercial Access – Market Comparison

    COMMERCIAL ACCESS – MARKET COMPARISON JA T E N Z O H A S C O M PE T I T I V E C O V E R A G E T H R O U G H O U T 2 0 2 1 0 . 00 % 10 . 00 % 90.00% 80.00% 70.00% 60 . 00 % 50.00% 40.00% 30.00% 20.00% 100.00% And r oderm And r oGel X y osted JATE N ZO Current JATENZO 2021 Target Co m mercia l Li v es

  21. Slide 21: JATENZO Demand Sales Growth Since Launch

    2020 DEMAND SALES JA T E N Z O H A S C O N SI ST E N T L Y G R O W N SI N C E L A U N C H D E SPI T E T H E PA N D E M I C A N D C O M M E R C I A L PA Y O R C O V E R A G E JATENZO TRxs Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Total Actuals 1 46 165 218 279 432 677 837 951 1,065 1,127 1,373

  22. Slide 22: Empower the Patient: DTC and Spokesperson

    DTC • Launch Date: Q4/2021 21 22 Spokesperson • Launch Date: Q4/2021 • In Active Negotiations EMPOWER THE P ATIENT: DTC AND SPOKES P ERSON A C C E L E R A T E JA T E N Z O PA T I E N T A W A R E N E SS T O D R I V E SW I T C H R A T E

  23. Slide 23: Expanding the Sales Force

    EXPANDING THE SALES FORCE C R E A T E S T H E N A T I O N A L F O O T PR I N T T O D E L I V E R O N B R A N D ST R A T E G I E S – M A X I M I Z I N G SA L E S I M PA C T • Sales Force Expansion Objective • Ex p an d national fo o tprin t fr o m 55 t o 101 territor i es • 85% TRT marke t coverage •

  24. Slide 24: Potential Growth Areas

    • JATENZO out - licensing opportunities to recognize incremental and ongoing revenue with: – Europe – Asia – Middle East • Actively pursuing complimentary products for in - licensing / acquisition – HAVAH T+Ai ™ (CLAR - 121) – Worldwide (excluding Australia) development and commercialization rights

  25. Slide 25: HAVAH T+Ai (CLAR-121) Inflammatory Periductal Mastitis

    • Initial clinical target : Inflammatory periductal mastitis - Painful, debilitating inflammation of breast tissue – predominantly in women - No effective pharmaceutical intervention - Early clinical data suggests that CLAR - 121 activates androgen - dependent anti - inflammatory mechanism in breast

  26. Slide 26: HAVAH T+Ai (CLAR-121) ER+ Breast Cancer

    HAVA H T+ A i (CLA R - 121) A D D I T I O N A L O PPO R T U N I T Y F O R A D JU N C T I V E T H E R A PY F O R E R + B R E A ST C A N C E R PA T I E N T S • Additional clinical target : Adjunctive therapy in ER+ breast cancer - An drogen recepto r (AR) h a s a n imp o rtan t t u m o r s u ppressor

  27. Slide 27: Expansion Opportunities for JATENZO R&D Pipeline

    Additional licensing opportunities to expand development pipeline EXPANSION OPPORTUNITIE S FOR J ATENZO R & D PI PE L I N E T R A N SF O R M S C L A R U S I N T O A B I O PH A R M A C E U T I C A L C O M PA N Y 2021 2022 Product Company Indication Q1’21 Q2’21 Q3’21 Q4’21 Q1’22 Q2’22 Q3’22 Q4’22 JATE

  28. Slide 28: Robust IP and Regulatory Exclusivity

    R O B U S T I P A N D R E G U L A T O R Y E X C L U S I V I T Y I S A S I G N I F I C A N T A D V A N T A G E F O R J A T E N Z O ® C L A R U S P R E V A I L E D I N P A T E N T I N F R I N G E M E N T L A W S U I T B R O U G H T B Y L I PO C I N E , I N C . INTELLECTUAL PROPE R TY OVERVIEW • Robust

  29. Slide 29: Transaction Summary

    29 Transaction Summary

  30. Slide 30: Transaction Summary: Clarus + Blue Water

    1. Exact amount dependent on final Investment amounts and redemptions at de - SPAC. • Business Combination and investment by Clarus stakeholders announced in Q2 2021 • Transaction closing expected in Q3 2021 Transaction Structure • $70 - 80MM pro forma cash (1) • $25MM H.I.G. Capital and insiders pr

  31. Slide 31: Comparable Company Analysis

    $ 6 5.0 $22 .0 $7 .0 $ 2 .0 $ 2 ,5 5 4 $2 , 08 5 $ 1 ,3 1 8 $670 $481 $2 , 34 9 $1 , 65 2 $1 , 26 6 $657 $506 COMAPARABL E CO M PANY ANALYSIS Source: Company filings, Capital IQ and Wall Street research as of 04/30/2021. (1) Total addressable market and patient population figures for lead product ca

  32. Slide 32: Comparable Company Analysis (Cont.)

    COMPARABL E CO M PANY ANALYSIS ( Cont . ) Price (4/30/2021) F D M a r k e t Cap F D E n t e r p r i se Value Sales (1) ($mm) Sales Growth (%) E V / R e v e nu e (x) Company ($) ($mm) ($mm) 2021E 2022E 2023E 2021E 2022E 2023E CAGR (2) 2021E 2022E 2023E Hims & Hers $12.38 $2,554 $2,349 202 240 287 40%

  33. Slide 33: Pro Forma Equity Ownership

    Source: Company internal data 1. The amounts from the various sources of cash may change based on (i) the amount of Public Stockholder redemptions prior to Closing, (ii) investor interest in the Acquisition and (iii) the then current markets for equity and debt financing. 2. Includes the Interim Fun

  34. Slide 34: Key Takeaways

    RIGH T TEAM Highly relevant TRT experience with a track record of success NOVE L TECH N OLOGY JATE N ZO – First an d o n ly FD A - app r ove d ora l T product o f its ki n d in a l arge an d g row i ng TRT marke t * AT T RACT I V E OPPORT U NI T Y A high - growth category with attractive net revenue

Blue Water Acquisition — SPAC Merger (June 2021) on 6ix